logo

For the Inventor, By the Inventor

Princeton, NJ, United States of America

Gang Wu

This inventor holds 20 USPTO granted patents and 2 published patent applications and 6 EPO patents, primarily in Pharmaceutical Chemistry. Top assignees: Bristol-Myers Squibb Compnay, Bristol Meyers Squibb Company, New Jersey Institute of Technology. Active years: 2002-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Gang Wu. Retrieved from https://idiyas.com/inventor/gang-wu-mqlh33bl

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 20 

% Patents Active = 100.0

 

Average Co-Inventor Count = 4.3

ph-index = 7

Forward Citations = 592(Granted Patents)


Company Filing History:

goldMedal18 out of 3,742 
 
Bristol-Myers Squibb Compnay
 patents
silverMedal1 out of 41 
 
Bristol Meyers Squibb Company
 patents
bronzeMedal1 out of 387 
 
New Jersey Institute of Technology
 patents
4. 1 out of 547 
 
Purdue Pharma L.p.
 patents
where one patent can have more than one assignee

Years Active: 2002-2025

Loading Chart...
Loading Chart...
Areas of Expertise:
TLR9 Inhibitors
Farnesoid X Receptor
GPR119 Modulators
Ion Channel Ligands
CB2 Agonists
Cannabinoid Receptor
Glycogen Phosphorylase Inhibitors
SGLT2 Inhibitors
Pharmaceutical Chemistry
Multicyclic Compounds
Spirocyclic Compounds
Pyrimidinylpiperidine
20 patents (USPTO):Explore Patents
1. 12486267 - Imidazo[1,2-A]pyridine and [1,2,4]triazolo[1,5-A]pyridine derivatives as TLR9 inhibitors for the treatment of fibrosis (2025-12-02),
2. 11370785 - Multicyclic compounds as farnesoid X receptor modulators (2022-06-28),
3. 11078198 - Spirocyclic compounds as farnesoid X receptor modulators (2021-08-03),
4. 9174965 - Pyrimidinylpiperidinyloxypyridone analogues as GPR119 modulators (2015-11-03),
5. 8421484 - Dielectric spectroscopy assays for screening of ion channel ligands (2013-04-16),
6. 8372837 - Pyridone and pyridazone analogues as GPR119 modulators (2013-02-12),
7. 7943658 - Indole indane amide compounds useful as CB2 agonists and method (2011-05-17),
8. 7572808 - Triazolopyridine cannabinoid receptor 1 antagonists (2009-08-11),
9. 7517991 - N-sulfonylpiperidine cannabinoid receptor 1 antagonists (2009-04-14),
10. 7452892 - Triazolopyrimidine cannabinoid receptor 1 antagonists (2008-11-18),
11. 7425550 - Lactam glycogen phosphorylase inhibitors and method of use (2008-09-16),
12. 7378418 - Azabicyclic heterocycles as cannabinoid receptor modulators (2008-05-27),
13. 7365061 - 2-Amino-3-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors (2008-04-29),
14. 7276608 - Tetrahydroquinoline derivatives as cannabinoid receptor modulators (2007-10-02),
15. 7214704 - 2-Amino-1-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors (2007-05-08),

Sure, I'd be glad to help you with that. Please find below the article about inventor Gang Wu:

Title: The Innovations of Gang Wu: Pioneering Solutions in Pharmacy

Introduction: Gang Wu, a brilliant inventor based in Princeton, NJ, has made significant contributions to the field of pharmaceuticals with his inventive compounds. With a total of 19 patents to his name, Gang Wu is at the forefront of developing cutting-edge solutions in the industry.

Latest Patents:

Gang Wu's latest patents include Multicyclic compounds as farnesoid X receptor modulators and Spirocyclic compounds as farnesoid X receptor modulators. These compounds have shown promising potential in modulating the activity of farnesoid X receptor (FXR) and treating various diseases and conditions associated with FXR dysregulation.

Career Highlights:

Throughout his career, Gang Wu has demonstrated a strong commitment to innovation and scientific excellence. He has worked with reputable companies such as Bristol-Myers Squibb Company and Purdue Pharma L.P., where he has played a pivotal role in developing groundbreaking pharmaceutical compounds.

Collaborations:

In his pursuit of innovation, Gang Wu has collaborated with esteemed professionals in the field, including Philip Michael Sher and Bruce A. Ellsworth. These collaborative efforts have led to the development of novel compounds that have the potential to revolutionize the pharmaceutical industry.

Conclusion:

In conclusion, Gang Wu's dedication to innovation and his pioneering work in developing novel pharmaceutical compounds have positioned him as a prominent figure in the field. His latest patents exemplify his commitment to pushing the boundaries of scientific discovery and his contributions are poised to have a lasting impact on the field of pharmacy.

If you have any other requests or need further information, feel free to ask!

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…